ADAP - Adaptimmune shares rise on mid-stage cancer trial data ahead of ASCO21

Adaptimmune Therapeutics shares rise ([[ADAP]] +4.9%) as the company talked up initial data from its mid-stage afamitresgene autoleucel cancer trial ahead of its presentation at the upcoming American Society of Clinical Oncology ((ASCO)) congress.At the time of data cut-off, 37 patients had received afami-cel (32 with synovial sarcoma, 5 with myxoid/ round cell liposarcoma [MRCLS]).The overall response rate was 39.3% (13/33), 41.4% (12/29) for synovial sarcoma; 25.0% (1/4) for MRCLS.Of the 29 patients with synovial sarcoma with at least one scan, 2 had complete responses ((CRs)), 10 had partial responses ((PRs)), 13 had stable disease ((SD)), 4 had progressive disease ((PD)).The disease control rate for people with synovial sarcoma was 86.2% (25/29) (defined as either response or stable disease).The safety profile of afami-cel has been favorable, with mainly low-grade cytokine release syndrome and tolerable/reversible hematologic toxicities, the company said.#ASCO21

For further details see:

Adaptimmune shares rise on mid-stage cancer trial data ahead of ASCO21